Alzecure: Jan Lundberg proposed as board member - Redeye

Redeye endorses today’s news that the nomination committee has proposed Jan Lundberg, Eli Lilly's and AstraZeneca's former head of research, as a new board member of Alzecure. We give a short comment.

Länk till analysen i sin helhet: https://www.redeye.se/research/995045/alzecure-jan-lundberg-proposed-as-board-member?utm_source=finwire&utm_medium=RSS